CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Påarp, Sweden

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

    Phase

    3

    Span

    239 weeks

    Sponsor

    Janssen Research & Development, LLC

    Shinjuku

    Recruiting

  • JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

    Participants will undergo a screening assessment over a period of less than or equal to (<=) 28 days to determine eligibility. Eligible participants will be treated by the Investigator's choice of RT alone or RT in combination with cetuximab. Following the Investigator's choice, participants will be randomized in a 1:1 ratio: - Arm A: JNJ-90301900 (NBTXR3), as an intratumoral/intranodal injection, activated by investigator's choice of RT alone or RT in combination with cetuximab - Arm B: Investigator's choice of RT alone or RT in combination with cetuximab All participants (Arm A and Arm B) will receive 70 Gy in 35 fractions over a 7 week period. An EOT visit will be performed 4 weeks after the completion of RT. Follow-up visits will start at 12 weeks post-RT completion, and will continue every 12 weeks for 2 years, and then every 24 weeks thereafter until death; the participant is determined to be lost to follow up; withdrawal of consent; or the end of the study, whichever occurs first. Participants who have received further anti-cancer therapy for the study disease and/or have had disease progression/recurrence will be followed only for survival information

    Phase

    3

    Span

    283 weeks

    Sponsor

    Johnson & Johnson Enterprise Innovation Inc.

    Tokyo

    Recruiting

  • An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

    Phase

    1/2

    Span

    213 weeks

    Sponsor

    JCR Pharmaceuticals Co., Ltd.

    Tokyo

    Recruiting

  • A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

    This is an open-label, multicenter, Phase 1/1b study of ALTA2618, a mutant-selective and orally bioavailable AKT1 E17K inhibitor, in adults with AKT1 E17K-mutant solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity of ALTA2618, and aims to find the best dose. The study consists of two parts: Part 1 - Dose Escalation and Part 1b - Dose Expansion.

    Phase

    1

    Span

    175 weeks

    Sponsor

    Alterome Therapeutics, Inc.

    Tokyo

    Recruiting

  • A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

    Phase

    2

    Span

    142 weeks

    Sponsor

    GlaxoSmithKline

    Tokyo

    Recruiting

  • A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

    Phase

    1/2

    Span

    287 weeks

    Sponsor

    Servier Bio-Innovation LLC

    Tokyo

    Recruiting

  • A Study of ZW191 in Participants With Solid Tumors

    Part 1 of the study will evaluate the safety and tolerability of ZW191. Part 2 of the study will further evaluate safety and explore the potential anti-tumor activity of ZW191.

    Phase

    1

    Span

    118 weeks

    Sponsor

    Zymeworks BC Inc.

    Tokyo

    Recruiting

  • A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

    Phase

    3

    Span

    58 weeks

    Sponsor

    GlaxoSmithKline

    Tokyo

    Recruiting

    Healthy Volunteers

  • A Study of GSK5764227 in Participants With Advanced Solid Tumors

    Phase

    1

    Span

    129 weeks

    Sponsor

    GlaxoSmithKline

    Tokyo

    Recruiting

  • A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

    This study consists of 2 parts: Part A and Part B. Part A: Participants who did not participate in either parent study (TAK-279-3001 [NCT06088043] or TAK-279-3002 [NCT06108544]) may be enrolled and will be treated for up to 52 weeks. Participants who successfully complete Part A of the study are eligible to continue in Part B, but investigators must confirm their eligibility to continue in Part B. Part B: Participants who complete the treatment period of TAK-279-3001 (NCT06088043) or TAK-279-3002 (NCT06108544) parent studies or who complete Part A are eligible to enroll directly into open label extension treatment in Part B and will be treated for up to 156 weeks.

    Phase

    3

    Span

    88 weeks

    Sponsor

    Takeda

    Tokyo

    Recruiting

1-10 of 322
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information